PainTEQ's Strategic Innovations Set to Transform SI Joint Care at NANS 2026

PainTEQ’s Strategic Innovations Set to Transform SI Joint Care at NANS 2026

PainTEQ, a front-runner in developing minimally invasive solutions for sacroiliac joint dysfunction, has made headlines with its significant investment in clinical and commercial operations shortly before the North American Neuromodulation Society (NANS) 2026 Annual Meeting. This bold move is set to not only elevate the brand's profile but also enhance the patient care experience in a critical medical field.

The company is distinguishing itself by focusing on continuous product innovation and validating its effectiveness through rigorous clinical research. This newly revitalized strategy emerges from the momentum gained during 2025, following significant recapitalization led by prominent partners, including Signet Healthcare Partners and Windham Capital Partners. With key industry figures like Mike Sherman and Robert Kline occupying roles on the board of directors, PainTEQ is poised to redefine SI joint care standards in 2026.

Among the major changes is the appointment of Lalit Venkatesan as Senior Vice President of Clinical Research, where he will champion the expansion of an evidence-based product line. Venkatesan is recognized for creating robust clinical trial designs, which will support a range of promising studies including a landmark Randomized Controlled Trial (RCT). This pivotal research will not only reinforce PainTEQ’s position against traditional surgical interventions but also promote new, safer options for pain management professionals.

Accelerating Product Pipeline

Building on the promise of superior patient outcomes, PainTEQ is also on a fast track to launching multiple innovative products within the next year, starting in the first quarter of 2026. CEO Shanth Thiyagalingam expressed confidence in this strategic direction, citing that the groundwork laid during the prior year positions PainTEQ for a leading market presence in 2026. “With the team and strategy in place, we are deploying the resources to scale,” Thiyagalingam remarked. The upcoming NANS event symbolizes a new chapter for PainTEQ, benefiting not only the company itself but also the countless patients who depend on effective treatment solutions.

Engaging the Community at NANS 2026

At NANS 2026, PainTEQ plans to host multiple activities designed to foster education, collaboration, and clinical dialogue within the interventional pain community. Attendees will have numerous chances to interact with key opinion leaders and the PainTEQ team at key locations during the event. Some prominent engagements include:

- PainTEQ Booth

Location: Booth #443 (NANS Exhibit Hall)

- PainTEQ Presentation

Title: LinQ Real-World Evidence and Complex SIJF Case Presentation
Presenters: Ramo Naidu, MD; Chris Bovinet, DO; Morad Nasseri, MD
Date: Thursday, January 22, 2026
Time: 7:30 PM – 8:00 PM
Venue: NANS Exhibit Hall (Innovation Theater Stage)

- Exclusive Customer Event: IGNITE

Presenters: Shanth Thiyagalingam, Tim Deer, MD; Dawood Sayed, MD; Jordan Tate, MD, MPH; Leonardo Kapural, MD, PhD
Date: Friday, January 23, 2026
Time: 9:00 PM – 10:00 PM
Venue: Toca Madera Las Vegas

PainTEQ continues to strive towards advancing healthcare for patients suffering from SI joint dysfunction through innovations like their LinQ implant. These advancements aim to provide immediate clinical benefits to those enduring debilitating lower back pain in a minimally invasive outpatient procedure.

For more information about PainTEQ and its offerings, visit www.painteq.com. This forward-thinking approach is set to revolutionize the treatment landscape, proving that with strategic expansion and innovative thinking, PainTEQ is ready for the future of pain management.